Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide plus taxane versus taxane alone in metastatic castration-resistant prostate cancer
NL-OMON53373Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Nov 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of darolutamide, docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Started Nov 2023; status: recruiting.
02
Drugs
darolutamidedocetaxelcabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON53373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53373.